A Prospective Multicenter Single-Arm Staged Study to Evaluate the Plan Title: Safety and Effectiveness of EmbraceTM Hydrogel Embolic For Transcatheter Embolization of Arterial Bleeding in Solid Organs and Peripheral Arteries

Enrolling By Invitation
99 years or below
All
1 Location

Brief description of study

This is a prospective, multicenter, single arm, staged clinical study. The study is designed to assess the safety and effectiveness of Embrace Hydrogel Embolic System when used for transarterial embolization for the treatment of arterial bleeding in solid organs and the peripheral vasculature, documented on suitable radiographic and/or endoscopic imaging performed during the index hospitalization. A minimum of 118 subjects will be treated with the Embrace Hydrogel in this study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All


Updated on 17 Jun 2025. Study ID: 23-0424
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research